Post-stroke depression: mechanisms and pharmacological treatment

RF Villa, F Ferrari, A Moretti - Pharmacology & therapeutics, 2018 - Elsevier
Depression, the most frequent psychiatric disorder following ischaemic stroke, negatively
affects survivals' functional outcome, response to rehabilitation and quality of life …

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

GS Malhi, D Bassett, P Boyce… - Australian & New …, 2015 - journals.sagepub.com
Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

RS McIntyre, M Alsuwaidan, BT Baune, M Berk… - World …, 2023 - Wiley Online Library
Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

A Cipriani, TA Furukawa, G Salanti, JR Geddes… - The lancet, 2009 - thelancet.com
Background Conventional meta-analyses have shown inconsistent results for efficacy of
second-generation antidepressants. We therefore did a multiple-treatments meta-analysis …

The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat

L Desbonnet, L Garrett, G Clarke, J Bienenstock… - Journal of psychiatric …, 2008 - Elsevier
It is becoming increasingly apparent that probiotics are important to the health of the host.
The absence of probiotic bacteria in the gut can have adverse effects not only locally in the …

The importance of norepinephrine in depression

C Moret, M Briley - Neuropsychiatric disease and treatment, 2011 - Taylor & Francis
Depression is one of the most common psychological diseases with significant potential
morbidity and mortality. Although the underlying pathophysiology of depression has not …

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines

A Cleare, CM Pariante, AH Young… - Journal of …, 2015 - journals.sagepub.com
A revision of the 2008 British Association for Psychopharmacology evidence-based
guidelines for treating depressive disorders with antidepressants was undertaken in order to …

A brief history of the development of antidepressant drugs: from monoamines to glutamate.

TM Hillhouse, JH Porter - Experimental and clinical …, 2015 - psycnet.apa.org
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that
is the most common mood disorder in the United States. It has been almost 50 years since …

Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder

B Bang-Andersen, T Ruhland… - Journal of medicinal …, 2011 - ACS Publications
The synthesis and structure− activity relationship of a novel series of compounds with
combined effects on 5-HT3A and 5-HT1A receptors and on the serotonin (5-HT) transporter …

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

C De Bodinat, B Guardiola-Lemaitre… - Nature reviews Drug …, 2010 - nature.com
Current management of major depression, a common and debilitating disorder with a high
social and personal cost, is far from satisfactory. All available antidepressants act through …